Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.55 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629587 | 0.92 | SCN3A (0.57) | SCN3AMGAT2SCN9AMEN1KMT2A | |
| SCHEMBL1102115 | 0.88 | CHRM2 (0.52) | SCN3ASCN9ASMN1; SMN2LMNATSHR | |
| SCHEMBL1102139 | 0.87 | LMNA (0.57) | SCN3ASMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL1102137 | 0.83 | CHRM2 (0.60) | SCN9ARORCMEN1KMT2A | |
| SCHEMBL9972209 | 0.78 | SCN3A (0.57) | SCN3ASMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL13637929 | 0.76 | SCN3A (0.41) | SCN3ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL10201439 | 0.74 | CYP1A2 (0.48) | LMNACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1102070 | 0.74 | CHRM2 (0.65) | SCN3ASCN9ASMN1; SMN2LMNATSHR | |
| SCHEMBL1102024 | 0.74 | MEN1 (0.64) | SCN9ASMN1; SMN2LMNARORCMEN1 | |
| SCHEMBL9972260 | 0.73 | MEN1 (0.54) | SCN3ASMN1; SMN2LMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | SCN3A 17/4885MGAT2 2033/4885SCN9A 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.